1. Home
  2. TIC vs ZYME Comparison

TIC vs ZYME Comparison

Compare TIC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TIC

Acuren Corporation Common Stock

HOLD

Current Price

$9.55

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.64

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIC
ZYME
Founded
1991
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TIC
ZYME
Price
$9.55
$26.64
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$14.17
$28.50
AVG Volume (30 Days)
3.6M
1.9M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,284,070,000.00
$134,481,000.00
Revenue This Year
$41.97
$64.45
Revenue Next Year
$42.94
$67.04
P/E Ratio
N/A
N/A
Revenue Growth
16.15
116.21
52 Week Low
$8.76
$9.03
52 Week High
$14.94
$28.49

Technical Indicators

Market Signals
Indicator
TIC
ZYME
Relative Strength Index (RSI) 36.46 68.38
Support Level $8.81 $24.83
Resistance Level $9.77 $28.49
Average True Range (ATR) 0.39 1.57
MACD 0.09 0.15
Stochastic Oscillator 75.38 70.98

Price Performance

Historical Comparison
TIC
ZYME

About TIC Acuren Corporation Common Stock

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: